CTMX CytomX
- 1.995
- +0.105+5.56%
CytomX News
Shareholders May Find It Hard To Justify Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For Now
Key Insights CytomX Therapeutics will host its Annual General Meeting on 15th of May Total pay for CEO Sean McCarthy includes US$652.1k salary The total compensation is similar to the average for
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer
Wednesday, CytomX Therapeutics Inc (NASDAQ:CTMX) released initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-canc
Dow Jumps Over 150 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded higher midway through trading, with the Dow Jones index jumping over 150 points on Thursday.The Dow traded up 0.48% to 39,244.53 while the NASDAQ rose 0.32% to 16,354.20. The S&P 50
Earnings Call Summary | CytomX(CTMX.US) Q1 2024 Earnings Conference
The following is a summary of the CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript:Financial Performance:As of Q1 2024, CytomX reported a cash position of $150 million, expected to pr
BMO Capital Maintains Market Perform on CytomX Therapeutics, Raises Price Target to $3.59
BMO Capital analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Market Perform and raises the price target from $3.25 to $3.59.
HC Wainwright & Co. : The CytomX Therapeutics (CTMX.US) neutral rating was reaffirmed.
HC Wainwright & Co. : The CytomX Therapeutics (CTMX.US) neutral rating was reaffirmed.
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
CytomX Therapeutics Raised to Outperform From Neutral by Wedbush
CytomX Therapeutics Raised to Outperform From Neutral by Wedbush
Wedbush: Upgraded CytomX Therapeutics (CTMX.US) rating from neutral to better than the market rating, and adjusted the target price from $3.00 to $8.00.
Wedbush: Upgraded CytomX Therapeutics (CTMX.US) rating from neutral to better than the market rating, and adjusted the target price from $3.00 to $8.00.
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ:APP) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.The company posted revenue of $1.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3
CytomX Therapeutics (CTMX) has an average rating of hold and price targets ranging from $2.25 to $8, according to analysts polled by Capital IQ. Price: 3.1100, Change: -1.08, Percent Change: -25.78
CytomX Therapeutics Shares Are Trading Lower, Pulling Back After Surging After Hours Thursday Following Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study.
CytomX Therapeutics Shares Are Trading Lower, Pulling Back After Surging After Hours Thursday Following Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study.
Daily rights tracking | Tesla's bearish ratio soared, and big players' bets fell; after Shopify's performance, it plummeted by more than 18%, making 6 times more profit from multiple PUT orders
Nvidia's overnight options traded at 930,000, and the bullish ratio rose to 62%. Calls due on Friday with an exercise price of $910/900 were the highest, with 63,000 and 60,000, respectively, and the number of unclosed positions was 7,400 and 8,400, respectively.
Barclays Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)
CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical Study, Demonstrating a Favorable Safety Profile and...
CytomX Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Announced Initial Data From the Ongoing CX-904 Phase 1a Dose Escalation Clinical
CytomX Therapeutics Q1 2024 GAAP EPS $0.17 Beats $(0.06) Estimate, Sales $41.463M Beat $21.434M Estimate
CytomX Therapeutics (NASDAQ:CTMX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $(0.06) by 383.33 percent. The company reported quarterly sales of $41.46
CytomX Therapeutics Announces Initial Phase 1a Dose Escalation Data For Monotherapy CX-904; Demonstrated Favorable Safety Profile, Says 2 Of 6 Patients Confirmed Partial Response And All 6 Patients With Disease Control
CytomX Therapeutics Announces Initial Phase 1a Dose Escalation Data For Monotherapy CX-904; Demonstrated Favorable Safety Profile, Says 2 Of 6 Patients Confirmed Partial Response And All 6 Patients Wi
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M
04:43 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M
Analysis
Price Target
No Data
